Roche signs neu­rode­gen­er­a­tion pact with stealthy biotech, pri­mar­i­ly fo­cus­ing on ALS

Ear­li­er this week, Roche part­nered with a lit­tle-known biotech in a new neu­ro­log­i­cal dis­ease col­lab­o­ra­tion aim­ing to treat ALS and po­ten­tial­ly oth­er de­bil­i­tat­ing ill­ness­es.

The Big Phar­ma com­pa­ny teed up a new pact with Aquin­nah Phar­ma­ceu­ti­cals for an undis­closed sum, Roche an­nounced Tues­day, to ad­vance the biotech’s pre­clin­i­cal re­search. Aquin­nah and Roche will col­lab­o­rate on such re­search lead­ing up the se­lec­tion of one pro­gram, af­ter which Roche will han­dle all de­vel­op­ment re­spon­si­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER